查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611859

阴道炎治疗药物市场：按药物类型、给药方式、给药途径、分销管道划分 - 全球预测 2025-2030

Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阴道炎治疗药物市场价值为26亿美元，预计到2024年将达到27.6亿美元，复合年增长率为8.75%，到2030年将达到46.8亿美元。

阴道炎治疗市场包括阴道炎治疗方法的开发、生产和分销，发炎。细菌性阴道炎、酵母菌感染疾病和滴虫性阴道炎的流行凸显了对有效治疗方法的需求，这些都是全世界阴道炎的主要原因。主要用途包括抗生素和抗真菌药物等处方药，以及用于缓解症状和控制感染的非处方药。最终使用领域主要是医疗机构和药房，解决慢性和急性疾病。推动市场成长的因素包括女性生殖健康意识的提高、各种生活方式因素导致的感染疾病率的增加以及诊断技术的进步。新疗法和组合的推出为市场参与企业提供了扩大其投资组合的潜在机会。此外，女性健康领域研究经费的增加正在为新型生技药品和标靶治疗铺平道路。然而，挑战包括严格的监管核准、需要进行全面的临床试验以确保疗效和安全性，以及当前疗法可能抑制患者依从性的潜在副作用。新兴市场也受到限制获得医疗保健的社会经济因素的影响。创新应着重于开发更有效、见效快且副作用最小的治疗方法，包括利用生物技术的进步，例如基于微生物的治疗方法和个体化医疗。我们可以透过投资早期检测和预防的研究、扩大与大学和生物技术公司的合作伙伴关係以及推动治疗方案的前沿来发展我们的业务。竞争格局仍然分散，既有成熟的製药公司，也有新兴的新兴企业，显示竞争格局充满活力，具有巨大的创新和扩张空间。

主要市场统计
基准年[2023] 26亿美元
预测年份 [2024] 27.6亿美元
预测年份 [2030] 46.8亿美元
复合年增长率（%） 8.75%

市场动态：快速发展的阴道炎治疗市场的关键市场洞察

供需的动态交互作用正在改变阴道炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于感染疾病导致阴道炎的盛行率增加
    • 人们越来越意识到性健康如何影响女性
    • 人们越来越偏好微创医疗程序和先进的阴道产品
  • 市场限制因素
    • 治疗阴道炎的高成本
  • 市场机会
    • 治疗阴道感染疾病的诊断和治疗药物的技术进步
    • 对用于治疗阴道炎的凝胶和乳膏等标靶给药系统的需求
  • 市场挑战
    • 与使用阴道炎药物相关的副作用

波特五力：驾驭阴道炎药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解阴道炎治疗药物市场的外部影响

外部宏观环境因素在塑造阴道炎治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解阴道炎治疗药物市场的竞争状况

对阴道炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵阴道炎治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估阴道炎治疗药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘阴道炎治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阴道炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于感染疾病导致阴道炎的发生率增加
      • 提高人们对性健康如何影响女性的认识
      • 人们对微创医疗程序和先进的阴道产品越来越感兴趣。
    • 抑制因素
      • 治疗阴道炎费用高
    • 机会
      • 阴道感染疾病诊断和治疗的技术进步
      • 对用于治疗阴道炎的凝胶和乳膏等标靶给药系统的需求
    • 任务
      • 与使用阴道炎药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按类型分類的阴道炎治疗药物市场

  • 抗菌的
  • 抗真菌剂
  • 荷尔蒙

第七章阴道炎治疗药物市场：透过提供

  • 店面销售(OTC)
  • 处方笺

第八章阴道炎治疗药物市场：依给药途径

  • 口服
  • 话题

第九章阴道炎治疗药物市场：依分销管道分类

  • 医院
  • 药局
    • 离线
    • 在线的

第十章 北美及南美阴道炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第11章：亚太地区阴道炎治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲阴道炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Ltd.
  • Dare Bioscience, Inc.
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Enzo Biochem Inc.
  • Janssen Pharmaceuticals Inc.
  • Lumavita AG
  • Lupin Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Mission Pharmacal Company
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Perrigo Company plc
  • Pfizer Inc.
  • PhagoMed Biopharma GmbH
  • Sanofi SA
  • Starpharma Holdings Limited
  • Sun Pharmaceutical Industries Limited
  • TenNor Therapeutics Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Pharmaceuticals, Inc.
Product Code: MRR-8E22B61932BA

The Vaginitis Therapeutics Market was valued at USD 2.60 billion in 2023, expected to reach USD 2.76 billion in 2024, and is projected to grow at a CAGR of 8.75%, to USD 4.68 billion by 2030.

The vaginitis therapeutics market encompasses the development, production, and distribution of treatments for vaginitis, an inflammation of the vagina characterized by symptoms such as itching, discomfort, and discharge. The necessity for effective therapies is underscored by the prevalence of bacterial vaginosis, yeast infections, and trichomoniasis, which are leading causes of vaginitis worldwide. Key applications include prescription medications like antibiotics and antifungals, as well as over-the-counter products aimed at symptom relief and infection management. End-use sectors predominantly involve healthcare facilities and pharmacies, servicing both chronic and acute conditions. The market's growth drivers include increased awareness about female reproductive health, rising incidences of infections due to various lifestyle factors, and advancements in diagnostic techniques. The launch of new therapeutics and combination treatments presents potential opportunities for market players to expand their portfolios. Additionally, increased funding in women's health research is paving the way for novel biologics and targeted therapies. However, challenges include stringent regulatory approvals, the need for comprehensive clinical trials to ensure efficacy and safety, and the potential side effects of current therapies which can hinder patient compliance. The market is also affected by socio-economic factors that limit access to healthcare in developing regions. Innovation should focus on developing more effective, faster-acting treatments with minimal side effects, possibly leveraging biotechnological advances such as microbiome-based therapies and customized medicine. Business growth can be found in investing in research for early detection and prevention approaches, and expanding partnerships with universities and biotech companies to push the frontier of treatment options. The competitive landscape remains fragmented, with a mix of established pharmaceutical companies and emerging start-ups, suggesting a dynamic nature with substantial room for innovation and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.60 billion
Estimated Year [2024] USD 2.76 billion
Forecast Year [2030] USD 4.68 billion
CAGR (%) 8.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaginitis Therapeutics Market

The Vaginitis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of vaginitis caused by infections
    • Increasing awareness about the impacts of sexual health on women
    • Growing preference for minimally invasive medical procedures and advanced vaginal products
  • Market Restraints
    • High cost associated with the treatment of vaginitis
  • Market Opportunities
    • Technological advancement in diagnostics and therapeutics for treating vaginal infections
    • Demand for targeted delivery systems such as gels and creams for treating vaginitis
  • Market Challenges
    • Side effects associated with the use of vaginitis medications

Porter's Five Forces: A Strategic Tool for Navigating the Vaginitis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaginitis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaginitis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaginitis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaginitis Therapeutics Market

A detailed market share analysis in the Vaginitis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaginitis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaginitis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaginitis Therapeutics Market

A strategic analysis of the Vaginitis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaginitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dare Bioscience, Inc., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, Enzo Biochem Inc., Janssen Pharmaceuticals Inc., Lumavita AG, Lupin Pharmaceuticals Inc., Merck & Co., Inc., Mission Pharmacal Company, Mylan NV, Novartis AG, Novo Nordisk A/S, Perrigo Company plc, Pfizer Inc., PhagoMed Biopharma GmbH, Sanofi S.A., Starpharma Holdings Limited, Sun Pharmaceutical Industries Limited, TenNor Therapeutics Ltd, Teva Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Vaginitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-bacterial, Anti-fungal, and Hormone.
  • Based on Offering, market is studied across Over-The-Counter (OTC) and Prescription.
  • Based on Route of Administration, market is studied across Oral and Topical.
  • Based on Distribution Channel, market is studied across Hospital and Pharmacies. The Pharmacies is further studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of vaginitis caused by infections
      • 5.1.1.2. Increasing awareness about the impacts of sexual health on women
      • 5.1.1.3. Growing preference for minimally invasive medical procedures and advanced vaginal products
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of vaginitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics and therapeutics for treating vaginal infections
      • 5.1.3.2. Demand for targeted delivery systems such as gels and creams for treating vaginitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the use of vaginitis medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaginitis Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-bacterial
  • 6.3. Anti-fungal
  • 6.4. Hormone

7. Vaginitis Therapeutics Market, by Offering

  • 7.1. Introduction
  • 7.2. Over-The-Counter (OTC)
  • 7.3. Prescription

8. Vaginitis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Vaginitis Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Pharmacies
    • 9.3.1. Offline
    • 9.3.2. Online

10. Americas Vaginitis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaginitis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaginitis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch Health Companies Inc.
  • 3. Bayer AG
  • 4. Cipla Ltd.
  • 5. Dare Bioscience, Inc.
  • 6. Dr Reddy's Laboratories Ltd
  • 7. Eli Lilly and Company
  • 8. Enzo Biochem Inc.
  • 9. Janssen Pharmaceuticals Inc.
  • 10. Lumavita AG
  • 11. Lupin Pharmaceuticals Inc.
  • 12. Merck & Co., Inc.
  • 13. Mission Pharmacal Company
  • 14. Mylan NV
  • 15. Novartis AG
  • 16. Novo Nordisk A/S
  • 17. Perrigo Company plc
  • 18. Pfizer Inc.
  • 19. PhagoMed Biopharma GmbH
  • 20. Sanofi S.A.
  • 21. Starpharma Holdings Limited
  • 22. Sun Pharmaceutical Industries Limited
  • 23. TenNor Therapeutics Ltd
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Tolmar Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VAGINITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VAGINITIS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-FUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 232. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023